IMbrave150 — Atezolizumab Plus Bevacizumab Versus Sorafenib in Unresectable Hepatocellular Carcinoma

Phase 3 · 2020 · Hepatocellular Carcinoma

Design

Open-label trial randomizing untreated unresectable HCC 2:1 to atezolizumab plus bevacizumab versus sorafenib.

Population

Systemic-therapy-naive unresectable/metastatic hepatocellular carcinoma, Child-Pugh A liver function.

Primary Endpoint

overall survival (OS) and progression-free survival (PFS)

Key Result

Updated median OS 19.2 vs 13.4 mo (HR 0.66); PFS 6.9 vs 4.3 mo (HR 0.65); ORR ~30% vs 11%.

Guideline Impact

NCCN category 1 preferred first-line for advanced HCC